TrueBlue Reports Continued Net Loss, Margin Contraction, and $18.4M Asset Impairment in Challenging Year
TBI sits 17% above its 52-week low of $3.45.
Summary
TrueBlue, Inc. filed its annual 10-K, reporting a net loss of $48.0 million for fiscal 2025, a 310 basis point contraction in gross profit margin, and an $18.4 million asset impairment. The filing also details the recent credit facility amendment and ongoing shareholder activism.
Key Events · Earnings and Guidance · TBI
-
Annual Net Loss Reported
TrueBlue reported a net loss of $48.0 million for fiscal year 2025, an improvement from the $125.7 million net loss in 2024, but still indicating ongoing operational challenges.
-
Gross Profit Margin Contracts Significantly
Gross profit as a percentage of revenue decreased by 310 basis points to 22.8% in 2025, primarily due to a shift towards lower-margin staffing businesses and less favorable workers' compensation reserve adjustments.
-
Substantial Asset Impairment Charge
The company recorded an $18.4 million non-cash impairment charge on right-of-use and other long-lived assets, related to a sublease of its Chicago support center as part of a shift to a remote/hybrid work model.
-
Credit Facility Amended and Reduced
The filing confirms the January 30, 2026, amendment to its revolving credit facility, reducing the line of credit from $255 million to $175 million and converting it to an asset-based lending facility, reflecting tighter financial conditions. This event was previously disclosed on 2026-02-03.
Analysis · TBI · Trade & Services
TrueBlue, Inc.'s annual 10-K filing reveals a company grappling with significant financial and corporate governance challenges. While the net loss for fiscal 2025 improved compared to the prior year, the continued losses and a notable 310 basis point contraction in gross profit margin highlight ongoing operational pressures. The substantial $18.4 million non-cash impairment charge on long-lived assets, driven by a shift to remote work, indicates significant restructuring costs. The report also confirms the recent amendment to its credit facility, which reduces borrowing capacity and shifts to asset-based lending, signaling a tighter financial environment. This comprehensive annual report provides critical details on the company's financial health and strategic responses amidst a backdrop of shareholder activism and a defensive 'poison pill' measure, reinforcing the challenges TBI faces in improving profitability and shareholder value.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBI was trading at $4.05 on NYSE in the Trade & Services sector, with a market capitalization of approximately $135.3M. The 52-week trading range was $3.45 to $7.86. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.